USD 0.98
(0.15%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 6.14 Million USD | 54.85% |
2022 | 3.96 Million USD | 13.21% |
2021 | 3.5 Million USD | -66.35% |
2020 | 10.41 Million USD | -6.52% |
2019 | 11.14 Million USD | 204.86% |
2018 | 3.65 Million USD | 292.08% |
2017 | 932.34 Thousand USD | -50.51% |
2016 | 1.88 Million USD | 23.96% |
2015 | 1.51 Million USD | -76.32% |
2014 | 6.41 Million USD | 68.35% |
2013 | 3.81 Million USD | 3.79% |
2012 | 3.67 Million USD | 16.62% |
2011 | 3.14 Million USD | 33.71% |
2010 | 2.35 Million USD | -10.52% |
2009 | 2.63 Million USD | 139.65% |
2008 | 1.09 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 6.54 Million USD | 6.54% |
2024 Q2 | 6.49 Million USD | -0.83% |
2023 FY | 6.14 Million USD | 54.85% |
2023 Q4 | 6.14 Million USD | -5.68% |
2023 Q3 | 6.51 Million USD | 4.05% |
2023 Q2 | 6.26 Million USD | -3.77% |
2023 Q1 | 6.5 Million USD | 63.96% |
2022 FY | 3.96 Million USD | 13.21% |
2022 Q4 | 3.96 Million USD | 11.07% |
2022 Q3 | 3.57 Million USD | 20.71% |
2022 Q2 | 2.96 Million USD | 2.85% |
2022 Q1 | 2.87 Million USD | -17.89% |
2021 Q4 | 3.5 Million USD | 2.95% |
2021 FY | 3.5 Million USD | -66.35% |
2021 Q3 | 3.4 Million USD | -10.96% |
2021 Q1 | 4.1 Million USD | -60.56% |
2021 Q2 | 3.82 Million USD | -6.92% |
2020 Q1 | 14.69 Million USD | 31.85% |
2020 Q3 | 12.92 Million USD | -18.23% |
2020 Q4 | 10.41 Million USD | -19.39% |
2020 Q2 | 15.8 Million USD | 7.57% |
2020 FY | 10.41 Million USD | -6.52% |
2019 Q3 | 11.16 Million USD | 12.13% |
2019 Q2 | 9.95 Million USD | 98.53% |
2019 FY | 11.14 Million USD | 204.86% |
2019 Q1 | 5.01 Million USD | 37.24% |
2019 Q4 | 11.14 Million USD | -0.21% |
2018 Q2 | 639.25 Thousand USD | -18.42% |
2018 Q1 | 783.6 Thousand USD | -15.95% |
2018 Q3 | 2.38 Million USD | 273.74% |
2018 Q4 | 3.65 Million USD | 53.01% |
2018 FY | 3.65 Million USD | 292.08% |
2017 Q4 | 932.34 Thousand USD | -23.42% |
2017 FY | 932.34 Thousand USD | -50.51% |
2017 Q3 | 1.21 Million USD | -8.64% |
2017 Q2 | 1.33 Million USD | -10.18% |
2017 Q1 | 1.48 Million USD | -21.25% |
2016 FY | 1.88 Million USD | 23.96% |
2016 Q1 | 1.51 Million USD | -0.0% |
2016 Q4 | 1.88 Million USD | -1.14% |
2016 Q3 | 1.9 Million USD | -9.67% |
2016 Q2 | 2.1 Million USD | 38.81% |
2015 Q4 | 1.51 Million USD | -41.6% |
2015 Q3 | 2.6 Million USD | -62.23% |
2015 Q2 | 6.88 Million USD | 9.89% |
2015 FY | 1.51 Million USD | -76.32% |
2015 Q1 | 6.26 Million USD | -2.3% |
2014 Q3 | 5.07 Million USD | 20.86% |
2014 Q1 | 2.65 Million USD | -30.37% |
2014 FY | 6.41 Million USD | 68.35% |
2014 Q2 | 4.19 Million USD | 58.1% |
2014 Q4 | 6.41 Million USD | 26.53% |
2013 Q4 | 3.81 Million USD | 106.57% |
2013 Q1 | 3.65 Million USD | -0.47% |
2013 Q2 | 3.93 Million USD | 7.65% |
2013 Q3 | 1.84 Million USD | -53.11% |
2013 FY | 3.81 Million USD | 3.79% |
2012 Q4 | 3.67 Million USD | 37.42% |
2012 Q2 | 2.64 Million USD | -19.75% |
2012 Q1 | 3.29 Million USD | 4.59% |
2012 FY | 3.67 Million USD | 16.62% |
2012 Q3 | 2.67 Million USD | 1.11% |
2011 Q2 | 2.68 Million USD | -1.14% |
2011 Q1 | 2.72 Million USD | 15.51% |
2011 FY | 3.14 Million USD | 33.71% |
2011 Q3 | 2.74 Million USD | 2.2% |
2011 Q4 | 3.14 Million USD | 14.57% |
2010 Q1 | 2.75 Million USD | 4.5% |
2010 Q3 | 2.22 Million USD | 0.77% |
2010 Q2 | 2.21 Million USD | -19.55% |
2010 Q4 | 2.35 Million USD | 5.63% |
2010 FY | 2.35 Million USD | -10.52% |
2009 FY | 2.63 Million USD | 139.65% |
2009 Q4 | 2.63 Million USD | -2.14% |
2009 Q3 | 2.68 Million USD | 0.0% |
2008 FY | 1.09 Million USD | 0.0% |
2008 Q4 | 1.09 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Akoya Biosciences, Inc. | 126.59 Million USD | 95.146% |
AngioDynamics, Inc. | 112.08 Million USD | 94.517% |
AtriCure, Inc. | 147.76 Million USD | 95.841% |
Avinger, Inc. | 19.97 Million USD | 69.23% |
Azenta, Inc. | 351.22 Million USD | 98.25% |
BioLife Solutions, Inc. | 75.05 Million USD | 91.812% |
The Cooper Companies, Inc. | 4.1 Billion USD | 99.85% |
Daxor Corporation | 858.75 Thousand USD | -615.623% |
Ekso Bionics Holdings, Inc. | 16.31 Million USD | 62.325% |
Femasys Inc. | 9.4 Million USD | 34.645% |
GlucoTrack, Inc. | 1.7 Million USD | -259.805% |
Harvard Bioscience, Inc. | 64.29 Million USD | 90.441% |
Hologic, Inc. | 4.02 Billion USD | 99.847% |
ICU Medical, Inc. | 2.25 Billion USD | 99.727% |
Intuitive Surgical, Inc. | 2.04 Billion USD | 99.699% |
KORU Medical Systems, Inc. | 8.1 Million USD | 24.197% |
LeMaitre Vascular, Inc. | 48.87 Million USD | 87.427% |
Innovative Eyewear, Inc. | 659.93 Thousand USD | -831.222% |
Innovative Eyewear, Inc. | 659.93 Thousand USD | -831.222% |
Masimo Corporation | 1.67 Billion USD | 99.633% |
Microbot Medical Inc. | 3.82 Million USD | -60.624% |
Meihua International Medical Technologies Co., Ltd. | 25.07 Million USD | 75.494% |
Merit Medical Systems, Inc. | 1.12 Billion USD | 99.453% |
Nephros, Inc. | 3.5 Million USD | -75.434% |
NovoCure Limited | 783.63 Million USD | 99.216% |
NEXGEL, Inc. | 4.78 Million USD | -28.325% |
NEXGEL, Inc. | 4.78 Million USD | -28.325% |
Singular Genomics Systems, Inc. | 86.46 Million USD | 92.892% |
OraSure Technologies, Inc. | 52.17 Million USD | 88.221% |
Pro-Dex, Inc. | 23.34 Million USD | 73.673% |
Pulse Biosciences, Inc. | 16.44 Million USD | 62.628% |
Precision Optics Corporation, Inc. | 6.84 Million USD | 10.217% |
QuidelOrtho Corporation | 3.55 Billion USD | 99.827% |
Repligen Corporation | 853.2 Million USD | 99.28% |
Sanara MedTech Inc. | 29.28 Million USD | 79.014% |
STAAR Surgical Company | 102.73 Million USD | 94.018% |
Sharps Technology, Inc. | 3.85 Million USD | -59.416% |
Utah Medical Products, Inc. | 7.14 Million USD | 13.989% |
DENTSPLY SIRONA Inc. | 4.07 Billion USD | 99.849% |
Jin Medical International Ltd. | 8.92 Million USD | 31.138% |